Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BMLBMLKF 69 EV-to-EBITDA is 3.36 as of Jul. 22, 2026, which is 49% below its 10-year median of 6.56. GuruFocus rates BMLKF with a GF Score™ of 69/100 and a GF Value™ of $26.56. The stock has 2 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, BML ranks better than 91.45% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BML's enterprise value is $467.7 Mil.
BML's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $139.2 Mil. Therefore, BML's EV-to-EBITDA for today is 3.36.
The historical rank and industry rank for BML's EV-to-EBITDA or its related term are showing as below:
BMLKF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.83 Med: 6.56 Max: 54.34
Current: 3.64
During the past 13 years, the highest EV-to-EBITDA of BML was 54.34. The lowest was 0.83. And the median was 6.56.
BMLKF's EV-to-EBITDA is ranked better than 91.45% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.48
vs BMLKF: 3.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-22), BML's stock price is $25.207.
BML's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.347. Therefore, BML's PE Ratio (TTM) for today is 18.71.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
BML (OTCPK:BMLKF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BML's share price for today is $25.207.
BML's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.347.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BML's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BML's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BML EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BML's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BML's EV-to-EBITDA falls into.
BML's current Enterprise Value is $467.7 Mil.
BML's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $139.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BML (BMLKF) has a EV-to-EBITDA of 3.36 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BML. This is 49% below median its historical median of 6.56. Over the past decade, BML's EV-to-EBITDA has ranged from 0.83 to 54.34. According to the industry distribution chart, BML ranks #10 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 8.5%.
Is BML's EV-to-EBITDA too high?
BML's current EV-to-EBITDA of 3.36 is 49% below median its 10-year median of 6.56. Over the past 10 years, this metric has ranged from a low of 0.83 to a high of 54.34. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.48. BML's value of 3.36 is 76.8% below this industry median. Based on the distribution chart, BML ranks #10 out of 117 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BML has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does BML's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BML ranks #10 out of 117 companies for EV-to-EBITDA. This places BML in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.48. BML's value of 3.36 is 76.8% below this benchmark. Historically, BML's own EV-to-EBITDA has ranged from 0.83 to 54.34 over the past decade. While the company's 10-year median is 6.56 vs. the industry median of 14.48, BML has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.48, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BML's current EV-to-EBITDA of 3.36 is 76.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BML. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BML's current EV-to-EBITDA is 3.36, which is 49% below median its own 10-year median of 6.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BML stock overvalued right now?
BML (BMLKF) has a current EV-to-EBITDA of 3.36. The stock's GF Value™ is $26.56, compared to a current price of $25.21 — trading 5.1% below its estimated fair value. The current EV-to-EBITDA is 3.36, which is 49% below median its 10-year median of 6.56 and 76.8% below the Medical Diagnostics & Research industry median of 14.48. BML's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BML (BMLKF), the current EV-to-EBITDA is 3.36 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BML (BMLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BML stock appears to be undervalued.
The current stock price of $25.21 is trading 5.1% below its estimated GF Value™ of $26.56.
Key valuation signals for BMLKF:
EV-to-EBITDA: 3.36 (49% below median its 10-year median of 6.56)
GF Value™: $26.56 vs. price of $25.21 (5.1% below fair value)
Industry Position: 76.8% below the Medical Diagnostics & Research median (#10 of 117)
No single metric tells the full story. See the BMLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.
69GF Score
Get the complete analysis for BMLKF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMLKF has been successfully added to your 
